Mucosal immunopathogenesis of Francisella tularensis

被引:49
|
作者
Metzger, Dennis W. [1 ]
Bakshi, Chandra Shekhar [1 ]
Kirimanjeswara, Girish [1 ]
机构
[1] Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA
来源
FRANCISELLA TULARENSIS: BIOLOGY, PATHOGENICITY, EPIDEMIOLOGY, AND BIODEFENSE | 2007年 / 1105卷
关键词
Francisella; intranasal immunization; lung; mouse; IFN-gamma; innate immunity; adaptive immunity; antibody;
D O I
10.1196/annals.1409.007
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Respiratory infection with Francisella tularensis is the deadliest form of disease and represents the most likely route to be used by bioterrorists. Although mucosal surfaces represent the first line of defense against respiratory tularemia, and in fact, against the great majority of human pathogens, little is known about protective immunity at these sites. The objective of this chapter is to review recent data examining the importance of various pulmonary immune mechanisms in defense against F. tularensis infection and to evaluate potential strategies for induction of protective lung immunity. Aerosol and intranasal mouse infection models have yielded essentially equivalent results and have implicated an important role for Th1-type immune responses in protection, including IFN-gamma, TNF-alpha, and IL-12. The cells responsible for protection in the lung are not well-characterized but NK cells are an early target for activation after infection although it appears that CD8 T cells might be most critical for host resistance. In addition, it is becoming increasingly clear that antibodies can provide prophylactic and therapeutic protection against pulmonary infection but only in the presence of active cell-mediated immunity. In fact, in vitro exposure of resting macrophages to antibody-coated bacteria in the absence of IFN-gamma can actually enhance infection. Although various immune mechanisms can be shown to be important for protection against attenuated strains such as LVS, the real challenge for the future is to design efficacious approaches to prevent disease by highly virulent strains such as SchuS4.
引用
收藏
页码:266 / 283
页数:18
相关论文
共 50 条
  • [31] MAb to Francisella tularensis lipopolysaccharide
    Berry, Jody D.
    HYBRIDOMA, 2007, 26 (02): : 109 - 109
  • [32] Field detection of Francisella tularensis
    Berdal, BP
    Mehl, R
    Haaheim, H
    Loksa, M
    Grunow, R
    Burans, J
    Morgan, C
    Meyer, H
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2000, 32 (03) : 287 - 291
  • [33] Chlorine disinfection of Francisella tularensis
    O'Connell, H. A.
    Rose, L. J.
    Shams, A. M.
    Arduino, M. J.
    Rice, E. W.
    LETTERS IN APPLIED MICROBIOLOGY, 2011, 52 (01) : 84 - 86
  • [34] Humoral immunity to Francisella tularensis
    Kirimanjeswara, Girish
    Metzger, Dennis
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S243 - S243
  • [35] Francisella tularensis: Activation of the inflammasome
    Weiss, David S.
    Henry, Thomas
    Monack, Denise M.
    FRANCISELLA TULARENSIS: BIOLOGY, PATHOGENICITY, EPIDEMIOLOGY, AND BIODEFENSE, 2007, 1105 : 219 - 237
  • [36] Pathogenicity and virulence of Francisella tularensis
    Degabriel, Manon
    Valeva, Stanimira
    Boisset, Sandrine
    Henry, Thomas
    VIRULENCE, 2023, 14 (01)
  • [37] Francisella tularensis in rodents, China
    Zhang, Fang
    Liu, Wei
    Chu, May C.
    He, Jun
    Duan, Qing
    Wu, Xiao-Ming
    Zhang, Pan-He
    Zhao, Qiu-Min
    Yang, Hong
    Xin, Zhong-Tao
    Cao, Wu-Chun
    EMERGING INFECTIOUS DISEASES, 2006, 12 (06) : 994 - 996
  • [38] Environmental adaptation of Francisella tularensis
    Hazlett, Karsten R. O.
    Cirillo, Kerry A.
    MICROBES AND INFECTION, 2009, 11 (10-11) : 828 - 834
  • [39] Francisella tularensis genomics and proteomics
    Titball, Richard W.
    Petrosino, Joseph F.
    FRANCISELLA TULARENSIS: BIOLOGY, PATHOGENICITY, EPIDEMIOLOGY, AND BIODEFENSE, 2007, 1105 : 98 - 121
  • [40] Vaccination strategies for Francisella tularensis
    Isherwood, KE
    Titball, RW
    Davies, DH
    Felgner, PL
    Morrow, WJW
    ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (09) : 1403 - 1414